series-c-plus
Stage
2010
Founded
2
Investors
About
Verastem Oncology is a biopharmaceutical company focused on developing and commercializing new medicines for cancer patients. Their lead product candidate, VS-6766, is a RAF/MEK inhibitor currently in clinical trials for various solid tumors.
Explore Verastem Oncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.